Full text is available at the source.
Abstract
The association between glucagon-like peptide-1 receptor agonists and kidney cancer risk in patients after metabolic and bariatric surgery remains unclear.
- Kidney cancer is increasingly linked to obesity.
- Metabolic and bariatric surgery may lower the risk of some obesity-related cancers.
- Use of glucagon-like peptide-1 receptor agonists has risen following metabolic and bariatric surgery.
- This evaluation focuses on adults with type 2 diabetes and overweight or obesity.
- The relationship between GLP-1 RA initiation and kidney cancer risk is under investigation.
Simplified